Abstract
Background
Estrogen receptor (ER) and progesterone receptor (PR) status is pivotal to determining the prognosis and treatment of human epidermal growth factor 2 (HER2) receptor-negative invasive breast cancer. Frequently ER-positive (ER+) and/or PR-positive (PR+) cancers are labeled nonspecifically as “hormone receptor-positive” although only one is positive. This study aimed to evaluate and characterize the ER+PR− and ER−PR+ breast cancer phenotypes in reference to ER+PR+ cancers.
Methods
A retrospective cohort study of female patients with HER2-negative (HER2−) invasive breast cancer diagnosed in 2010−2015 was performed using the National Cancer Database. Cases were grouped into ER+PR+, ER−PR+, ER+PR−, and ER−PR− phenotypes to determine differences in patient demographics, tumor characteristics, and overall survival.
Results
Of 823,969 cases, 619,050 (75.1%) were ER+PR+, 79,777 (9.7%) were ER+PR−, 7006 (0.9%) were ER−PR+, and 118,136 (14.3%) were ER−PR−. Compared with the ER+PR+ group, the ER+PR− and ER−PR+ groups were more likely to be high-grade cancer (16.0% vs. 34.2% and 80.0%, respectively; p < 0.001), to have lymphovascular invasion (17.9% vs. 19.6% and 23.0%; p < 0.001), to be node-positive (13.5% vs. 19.7% and 26.3%; p < 0.001), to be stage 4 cancer (3.6% vs. 5.9% and 6.7%; p < 0.001), to have a higher multigene assay score (mean, 16.0 vs. 27.8 and 38.1; p < 0.001), and to have a worse survival (90.6% vs. 83.8% and 78.1%; p < 0.001).
Conclusion
Single hormone receptor-positive breast cancer subtypes (ER+PR− and ER−PR+) are more likely to have unfavorable characteristics and worse survival than the ER+PR+ subtype, with the ER−PR+ subtype having outcomes similar to those for ER−PR− cancers. The single hormone receptor-positive subtypes, representing 10% of HER2− cancers, should be considered clinically distinct from ER+PR+ disease.
Similar content being viewed by others
References
National Comprehensive Cancer Network Breast Cancer (version 3.2020). Invasive Breast Cancer, Systemic Adjuvant Treatment (BINV-4). Retrieved 1 May 2020 at https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf.
American Cancer Society. Breast Cancer Facts and Figures 2019–2020. Retrieved 30 April 2020 at https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/breast-cancer-facts-and-figures/breast-cancer-facts-and-figures-2019-2020.pdf.
De Maeyer L, Neven P, Drijkoningen R, et al. The estrogen receptor has a prognostic value in progesterone receptor-positive breast cancer. Int J Gynecol Cancer. 2006;16(Suppl2):589–98.
Rakha EA, El-Sayed ME, Green AR et al. Biologic and clinical characteristics of breast cancer with single hormone receptor-positive phenotype. J Clin Oncol. 2007;25:4772–8.
Bae SY, Kim S, Lee JH et al. Poor prognosis of single hormone receptor-positive breast cancer; similar outcome as triple-negative breast cancer. BMC Cancer. 2015;15:138.
Shen T, Brandwein-Gensler M, Hameed O, et al. Characterization of estrogen receptor-negative/progesterone receptor-positive breast cancer. Hum Pathol. 2015; 46:1776–84.
Chan M, Chang MC, Gonzalez R, et al. Outcomes of estrogen receptor-negative and progesterone receptor-positive breast cancer. PLoS ONE. 2015;10:e0132449.
Li Y, Yang D, Yin X, et al. Clinicopathological characteristics and breast cancer-specific survival of patients with single hormone-receptor breast cancer. JAMA Netw Open. 2020;3:e1918160.
American College of Surgeons. National Cancer Database. Retrieved 10 January 2020 at https://www.facs.org/quality-programs/cancer/ncdb/puf.
von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370:1453–7.
Chaudhary LN, Jawa Z, Szabo A, Visotchky A, Chitamber CR. Relevance of progesterone receptor immunohistochemical staining to Oncotype DX recurrence score. Hematol Oncol Stem Cell Ther. 2016;9:48–54.
Orucevic A, Bell JL, McNabb AP, and Heidel RE. Oncotype DX breast cancer recurrence score can be predicted with a novel nomogram using clinicopathologic data. Breast Cancer Res Treat. 2017;163:51–61.
Sparano JA, Gray RJ, Makower DF, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med. 2018;379:111–21.
Pease AM, Riba LA, Gruner RA, Tung NM, James TA. Oncotype DX® recurrence score as a predictor of response to neoadjuvant chemotherapy. Ann Surg. Oncol. 2019; 26:366–71.
Smid M, Wang Y, Zhang Y, et al. Subtypes of breast cancer show preferential site of relapse. Can Res. 2008;68:3108–14.
Anders CK, Carey LA. Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. Clin Breast Cancer. 2009;9(Suppl 2):S73–81.
National Comprehensive Cancer Network Breast Cancer (version 3.2020). Invasive Breast Cancer, Axillary Lymph Node Staging (BINV-E). Retrieved 1 May 2020 at https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf.
Hughes KS, Schnaper LA, Bellon JR, et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol. 2013;31:2382–7.
Kunkler IH, Williams LJ, Jack WJL et al. Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II). Lancet Oncol. 2015;16:266–73.
Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295:2492–502.
Kohler BA, Sherman RL, Howlader N, et al. Annual Report to the Nation on the status of cancer, 1975–2011, featuring incidence of breast cancer subtypes by race/ethnicity, poverty, and state. J Natl Cancer Inst. 2015;107:djv048.
De Maeyer L, Van Limbergen E, De Nys K, et al. Does estrogen receptor-negative/progesterone receptor-positive breast carcinoma exist? J Clin Oncol. 2008;26:335–6.
Hefti MM, Hu R, Knoblauch NW, et al. Estrogen receptor negative/progesterone receptor-positive breast cancer is not a reproducible subtype. Breast Cancer Res. 2013;15:R68.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Disclosure
Rowan T. Chlebowski is a consultant for Novartis, AstraZeneca, Genentech, Merck, Immunomedics, and Puma and received honorarium from Novartis and AstraZeneca.
Conflict of interest
The authors have no conflicts of interest to declare.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Disclaimer
The NCDB and the hospitals participating in the NCDB are the source of the de-identified data used in this study. They have not verified the statistical validity of the data analysis or the conclusions derived by the authors and are not responsible for them.
Rights and permissions
About this article
Cite this article
Dauphine, C., Moazzez, A., Neal, J.C. et al. Single Hormone Receptor-Positive Breast Cancers Have Distinct Characteristics and Survival. Ann Surg Oncol 27, 4687–4694 (2020). https://doi.org/10.1245/s10434-020-08898-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-020-08898-5